- Home
- RLAY vs ADEA Comparison
RLAY vs ADEA Comparison
Compare RLAY & ADEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- ADEA
- Stock Information
- Founded
- RLAY 2015
- ADEA 1990
- Country
- RLAY United States
- ADEA United States
- Employees
- RLAY N/A
- ADEA N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- ADEA Computer Software: Prepackaged Software
- Sector
- RLAY Health Care
- ADEA Technology
- Exchange
- RLAY Nasdaq
- ADEA Nasdaq
- Market Cap
- RLAY 576.1M
- ADEA 1.5B
- IPO Year
- RLAY 2020
- ADEA N/A
- Fundamental
- Price
- RLAY $3.60
- ADEA $14.74
- Analyst Decision
- RLAY Strong Buy
- ADEA Strong Buy
- Analyst Count
- RLAY 11
- ADEA 4
- Target Price
- RLAY $18.40
- ADEA $19.50
- AVG Volume (30 Days)
- RLAY 1.5M
- ADEA 561.2K
- Earning Date
- RLAY 08-05-2025
- ADEA 08-05-2025
- Dividend Yield
- RLAY N/A
- ADEA 1.36%
- EPS Growth
- RLAY N/A
- ADEA 89.09
- EPS
- RLAY N/A
- ADEA 0.66
- Revenue
- RLAY $7,679,000.00
- ADEA $380,289,000.00
- Revenue This Year
- RLAY $17.59
- ADEA $10.68
- Revenue Next Year
- RLAY N/A
- ADEA $4.16
- P/E Ratio
- RLAY N/A
- ADEA $22.26
- Revenue Growth
- RLAY N/A
- ADEA 7.16
- 52 Week Low
- RLAY $1.78
- ADEA $9.68
- 52 Week High
- RLAY $10.72
- ADEA $17.46
- Technical
- Relative Strength Index (RSI)
- RLAY 57.25
- ADEA 64.05
- Support Level
- RLAY $3.50
- ADEA $14.33
- Resistance Level
- RLAY $3.86
- ADEA $14.99
- Average True Range (ATR)
- RLAY 0.18
- ADEA 0.41
- MACD
- RLAY 0.02
- ADEA 0.07
- Stochastic Oscillator
- RLAY 65.79
- ADEA 88.64
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. Its only operating segment being Intellectual Property (IP) Licensing. In the IP segment, it primarily license innovations to leading companies in the broader entertainment industry, and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.